PIK3CD and leukemia: Several p110δ inhibitors, including idelalisib [162], duvelisib [163], and umbralisib [164], were previously approved by the U.S. Food and Drug Administration for treating various types of leukemia or lymphoma, given the dominant role of p110δ in hematopoietic malignancies.